Transfer factor

[Guest guest]

In a message dated 4/6/01 9:12:49 AM Central Daylight Time,

Ssadlermas@... writes:

<<

<< These are the ingredients in the TF Plus, right? My understanding is that

this isn't recommended for anyone w/autoimmune disorders - those folks

are suggested to use just the Transfer Factor (vs the TF Plus). >>

This is true but lyme is not an auto-immune disorder.

>>

OK, well, what if you are like me and Lyme has caused a dysfunctional immune

system? I technically also have Chronic Fatigue Immune Dysfunction Syndrome

also as I meet all the CDC criteria, have low Natural Killer Cells, out of

balance CD4-CD8 ratios, etc. Would it be detrimental to take it?

[Guest guest]

In a message dated 4/6/01 11:46:44 AM, golfdawg@... writes:

<< OK, well, what if you are like me and Lyme has caused a dysfunctional

immune

system? I technically also have Chronic Fatigue Immune Dysfunction Syndrome

also as I meet all the CDC criteria, have low Natural Killer Cells, out of

balance CD4-CD8 ratios, etc. Would it be detrimental to take it?

>>

I am not a dr. and I would advise that you call 4Life themselves and ask.

Technically from my resources lyme and chronic fatigue are basically one in

the same. We all have low NK cells, we are 'out of balance'. It is up to each

individual to make that judgment.

Sue in nj

[Guest guest]

In a message dated 4/6/01 11:46:44 AM, golfdawg@... writes:

<< OK, well, what if you are like me and Lyme has caused a dysfunctional

immune

system? I technically also have Chronic Fatigue Immune Dysfunction Syndrome

also as I meet all the CDC criteria, have low Natural Killer Cells, out of

balance CD4-CD8 ratios, etc. Would it be detrimental to take it?

>>

I am not a dr. and I would advise that you call 4Life themselves and ask.

Technically from my resources lyme and chronic fatigue are basically one in

the same. We all have low NK cells, we are 'out of balance'. It is up to each

individual to make that judgment.

Sue in nj

[Guest guest]

You should take the regular Transfer Factor not the plus as the plus increases natural killer cells which is what affects the body in autoimmune stages. .

FrancineRN NJ

[Guest guest]

It was originally thought that transfer factor could only be transferred

successfully through the blood, and thus was administered either by

injection or transfusion. The process of extracting the transfer factors

from blood was very costly and time consuming. Human blood sources included

live donors, outdated blood from blood banks, but using human blood sources

includes all the hazards associated with blood transfusions such as HIV and

Hepatitis. In additio, neither freshly drawn nor outdated blood from blood

banks was an adequate source for commerical transfer factor. Therefore,

large doses would be given a monthly basis. These studies were done in the

70's and 80's. Now many believe that the colostrum in diary milk is the best

source of transfer factor. Harvesting the excess colostrum and isolating

its transfer factor supply provides an abundant and beneficial source of

transfer factor for human consumption. Later more recent studies have shown

that transfer factor was equally as effective when taken orally. This

observation is consistent with studies on oral absorption of other peptides

of similar size.

Hope this answers your question? Jana

Transfer Factor

> Hi,

> Here is some more information on Transfer Factor.

> In one study below Transfer Factor was given once a month, yet people

using it for

> themselves usually take Transfer Factor daily. Why would they give it only

once a

> month in the clinical trial?

>

> moonbeam

>

> 1: Gan No Rinsho 1983 Oct;29(12):1409-16

>

> Transfer factor immunochemotherapy for primary lung cancer--evaluation of

> histologic types.

>

> [Article in Japanese]

>

> Fujisawa T, Yamaguchi Y

>

> The clinical effect of leucocyte dialysate, including Transfer Factor

(TF), on

> different histologic types of primary resected lung cancer was studied.

Eligible

> cases for evaluation were randomly chosen; the TF group and control group

consisted

> of 75 and 74 patients, respectively. The TF group included 40

adenocarcinomas, 29

> epidermoid carcinomas and 6 other histologic types of carcinoma. The

control group

> included 42 adenocarcinomas, 25 epidermoid carcinomas and 7 other

histologic types

> of carcinoma. The postoperative follow-up term was 2 to 55 months in

both groups.

> Survival in the TF group of patients with adenocarcinoma of stages I + II

or

> curative resection was significantly better than in the control group (p

less than

> 0.005, -Mantel test). There was no significant intergroup difference in

patients

> with stages III + IV, relative curative or noncurative resection. Survival

in

> the TF group of patients with epidermoid carcinoma of stages I + II or III

+ IV

> was about 20% better than in the control. Survival in the TF group of

patients

> undergoing relative curative resection was significantly better than in

> the control (p less than 0.005, -Mantel test).

> There was a significant difference between patients with stages I + II,

but not

> between patients with stages III + IV. The frequency of recurrence of

regional

> or intrapulmonary distant metastasis was lower in the TF group. It is

suggested

> that TF suppresses postoperative recurrence and that it may be beneficial

as

> postoperative adjuvant immunochemotherapy in primary resected lung cancer

> patients, especially those with relatively early stage cancer.

>

> PMID: 6315989

> --------------------------------------------------------------

>

> 1: Biotherapy 1996;9(1-3):117-21

>

> Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC)

therapy.

>

> Pilotti V, Mastrorilli M, Pizza G, De Vinci C, Busutti L, Palareti A,

Gozzetti

> G, Cavallari A

>

> Istituto di Clinica Chirurgica II, S. Orsola-Malpighi, Bologna, Italy.

>

> The rationale for using transfer factor (TF) in lung cancer patients is

that the

> possibility of improving their cell-mediated immunity to tumour associated

> antigens (TAA) may improve their survival. From Jan 1984 to Jan 1995, 99

> non-small cell lung cancer (NSCLC) resected patients were monthly treated

with

> TF, extracted from the lymphocytes of blood bank donors. In the same

period, 257

> NSCLC resected patients were considered as non-treated controls. The

survival

> rates of the TF treated group appear significantly improved both for

patients in

> stages 3a and 3b, and patients with histological subtype " large cell

carcinoma "

> (P < 0.02). Survival of TF treated patients is also significantly higher

(P <

> 0.02) for patients with lymph node involvement (N2 disease). The results

of this

> study suggest that the administration of TF to NSCLC resected patients may

> improve survival.

>

> Publication Types:

> Clinical trial

> Controlled clinical trial

>

> PMID: 8993769

> -------------------------------------------------------

>

> 1: Cancer Detect Prev Suppl 1987;1:373-6

>

> Transfer factor for adjuvant immunotherapy in cervical cancer.

>

> Wagner G, Knapp W, Gitsch E, Selander S

>

> 1st Department of Obstetrics and Gynecology, University of Vienna,

Austria.

>

> In a prospective randomized double-blind study of 60 patients with

invasive

> cervical cancer, 32 were treated with transfer factor (TF) derived from

> leukocytes of the patients' husbands, and 28 were treated with placebo.

Within

> the first 2 years after radical hysterectomy, five out of 32 TF-treated

patients

> and 11 out of 28 placebo-treated patients developed recurrence of

malignancy.

> This difference is significant (chi 2 = 3.9915; P less than 0.05).

>

> PMID: 3319147

> -----------------------------------------------------------------

>

> 1: Biotherapy 1996;9(1-3):123-32

>

> A preliminary report on the use of transfer factor for treating stage D3

> hormone-unresponsive metastatic prostate cancer.

>

> Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G,

> Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P,

Fornarola

> V, Viza D

>

> Reports have suggested the existence of

> humoral and cell-mediated immunity (CMI) against prostate cancer

> tumour-associated antigens (TAA).

> Fifty patients entered this study and received one intramuscular

injection of 2-5

> units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed

that

> complete remission was achieved in 2 patients, partial remission in 6, and

no

> progression of metastatic disease in 14. The median survival was 126

weeks,

> higher than the survival rates reported in the literature for patients of

the

> same stage.

>

> Publication Types:

> Clinical trial

>

> PMID: 8993770

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

> Get HUGE info at http://www.cures for cancer.ws, and post your own links there.

Unsubscribe by sending email to cures for cancer-unsubscribeegroups or by

visiting http://www.bobhurt.com/subunsub.mv

>

>

[Guest guest]

   hi feige2see,

<<< Anyone who has been on transfer factor seeing any results?I think I

read one message in the last three months >>>

i used to post periodic updates. haven't posted one in quite a while.

i still have a 14yr old (15 in a week) on the full dose of the 560 (3

capsules a day). she's been on it for about 16 months now. she DOES do

better, and i have no plans to take her off.

she had a bad " crash " over the winter (thanks to the school - long

story, but it's been resolved - think they have a bit of a " clue " now).

she starts 9th grade in the fall. she'll just do academics - so she'll

be prepared to pass a GED some day. she'll be taking two classes -

which they call " blocks " , an hour and a half each, a half day. it'll be

about 11:30am to 2:30pm. she'll then have a homebound teacher to help

her with those two classes.

it may turn out to be a bit too much, and she may not do great

grade-wise, but hopefully, she'll get enough out of it to pass the

GED... really have not idea at this point.

she seems pretty " happy " , " normal " , well adjusted at this point. she

WANTS to be at school. and of course wants to do a whole lot more than

she can, and attempts it ...

~~~~~~~~~~~~~~~~~~~~~~~~~

" Would they have found nothing, unless nothing was what they wanted to

find? " - Agent Dales, X-Files

@}{~{<<~~~~~~~~~~~~~~~~~~~~

@}{~{<<~~~~~~~~~~~~~~~~~~~~

debbie s. - dlsherman@...

[Guest guest]

All I have noticed is that it now makes me somewhat less sick when I take it

(once a week, TID)

> Anyone who has been on transfer factor seeing any results?I think I

> read one message in the last three months,where one person stated it

> helped.I started three months ago,several people in the group started

> the same time with heparin and isoprinosine,would like to hear how

> you are doing.

[Guest guest]

I have put my blab about this on www.austarmetro.com.au/~julian/tf.html

n

At 23:14 08/06/01, you wrote:

> > Anyone who has been on transfer factor seeing any results?I think I

> > read one message in the last three months,where one person stated it

> > helped.I started three months ago,several people in the group started

> > the same time with heparin and isoprinosine,would like to hear how

> > you are doing.

[Guest guest]

Thank you for your post on TF. I didn't have any luck with the colostrum doses

in Biomune OSF - was hoping plain old TF would be a better hammer (and more cost

effective). Question: do

dairy-allergic people have a potential problem here? I recently tried Immunocal

and don't know whether my reaction was allergic or die-off, and was considering

NAET treatment.

- N. in CA

n wrote:

> I have put my blab about this on www.austarmetro.com.au/~julian/tf.html

>

> n

>

> At 23:14 08/06/01, you wrote:

> > > Anyone who has been on transfer factor seeing any results?I think I

> > > read one message in the last three months,where one person stated it

> > > helped.I started three months ago,several people in the group started

> > > the same time with heparin and isoprinosine,would like to hear how

> > > you are doing.

>

> This list is intended for patients to share personal experiences with each

other, not to give medical advice. If you are interested in any treatment

discussed here, please consult your doctor.

>

>

[Guest guest]

I am dairy sensitive and can't use immunocal, but TF is no problem. TF

itself contains nothing that you are likely to be allergic to (no big

proteins or lactose), but sometimes it is packaged with small amounts of

milk product like whey. Even then I've not noticed a problem.

n

At 17:19 09/06/01, you wrote:

>was hoping plain old TF would be a better hammer (and more cost

>effective). Question: do

>dairy-allergic people have a potential problem here?

[Guest guest]

Hi Luke and n,

Have been reading your post about Transfer Factor C or Chisolm #2 with great

interest. Have dug out a long question and answer session of Dr. Fundenberg

back in 93'. He said the best Transfer Factor was from one person that had

lived with the ill person for at least 6 mos to get a good transfer factor

from their blood. He was helping too many people I guess and they finally

but him out of business. I had contacted him back then and he had sent me

papers to fill out but couldn't talk my husband into going to SC.

My question is and can't seem to find it in the web sites that I have looked

at is Transfer Factor #2 or TF C made from human blood? From what I have

gathered this is the best provided it is safe. I am very ill for a long time

and want to take the one where I would have the best change for improvement.

Would appreciate your opinions.

Thanks,

H.

[Guest guest]

At 06:48 29/07/01, you wrote:

>My question is and can't seem to find it in the web sites that I have looked

>at is Transfer Factor #2 or TF C made from human blood?

No - the only TF that I know is made from Human blood is the Cuban one that

is listed under links on my website. By definition this cannot be a

" specific " TF to all those bugs that TF#2 and TF C are supposed to be

specific to, cos how would you know that all the people who contributed

their blood had been exposed to HHV6 etc...?

I think the Chisolm products are made from some kind of cell-line culture

from chickens, but this might not be right... I must check at some stage.

The reason Fudenberg liked using a close relative/co-habiter is because he

could assume they had been exposed to whatever bugs were ailing you, so

that they would have TF specific to all your bugs. I guess the jury is out

as to how true that is in practice but it seems plausible. It seems he was

heavily pressured and it is sad that he eventually gave it away.

Cheers,

n

[Guest guest]

<<< The reason Fudenberg liked using a close relative/co-habiter is

because he could assume they had been exposed to whatever bugs were

ailing you, so that they would have TF specific to all your bugs. I

guess the jury is out as to how true that is in practice but it seems

plausible. It seems he was heavily pressured and it is sad that he

eventually gave it away. >>>

another problem with human tf is that it's extremely time consuming, and

prohibitively expensive - unfortunately, couldn't be mass produced....

~~~~~~~~~~~~~~~~~~~~~~~~~

" Would they have found nothing, unless nothing was what they wanted to

find? " - Agent Dales, X-Files

@}{~{<<~~~~~~~~~~~~~~~~~~~~

@}{~{<<~~~~~~~~~~~~~~~~~~~~

debbie s. - dlsherman@...

[Guest guest]

Moonbeam, (I know already what a profilic writer is, so I don't need your

answer any longer)

Good information. Thanks for this. But I got all this also from Felix

. And that makes it for me reasonable reliable, though I stay

suspicious as always (in a good way I hope) . Felix and his company give

also the studies where transfer factor plus didn't work. But what I see and

read is that transfer factor plus doesn't work on itself but as an adjuvant

with chemo, surgery and radiation it makes a difference. Often a significant

difference. Like almost all vitamins etc. do.

And remarkable, in the informationbook of transfer factor plus also beta

glucan, vitamin C, echinacea, berberine-containing herbs etc. are mentioned

to take together with transfer factor plus.

Important, but I don't know if this is true: I got information that the

company who sells transfer factor plus has got a patent on this product

because they isolated a certain substance and add then vitamins etc. (How do

you say that in english, boosting immunesystem products? ) which are not to

be patented. Then in studies when they have good results they give the

credits to the transfer factor, but they don't say anything about the

vitamin C for example because that aren't patented substances. But I've

heard this and cann't prove that with hard conclusions and written

statements. But it is remarkable because some Chinese herbs like Zhuling,

Kanglaite etc. show the same process when they are used as an adjuvant with

chemo , surgery and radiation.

Another thing what I see and read in all the information about transfer

factor plus is that transfer factor plus works better in cancers like

leukemia, non-Hogdkin etc. Blood and boonmarrow related kind of cancers.

Though the study with post surgery therapy also shows a good effect. I think

this is interesting and confirms in my opinion that every kind of cancer

needs a basic treatment of a good diet with supplements, but needs also a

specialised advise from a specialised orthomolecular doctor which

supplements are the best for that kind of cancer. Breastcancer needs a

different approach than leukemia for example. And confirms also in my

opinion the way of thinking that a good diet with certain nutritional

supplements in addition to regular treatments (not always though) will give

us more chance to survive our cancer. I think it isn't smart to skip all

regular treatment, though for certain cancers chemo doesn't work at all

(according to Ralph Moss, but that is mentioned before in this group) But

ofcourse one should always consult a specialised doctor.

Gr. Kees Braam

webmaster www.kanker-actueel.nl

Caroleans mother/transfer factor plus?

> > Did your mother tried Transfer factor plus?. It seems if I may believe

the

> > testimonials (I got them from the company who sells this product so

> > there is some suspicious reading needed)

>

> Hi,

> there is no need to be suspicious or to rely on testimonials.

Instead always

> search the medline for clinically proven results. I do that everyday.

> Transfer Factor is not the best immune stimulant, beta glucan is the best

and most

> comprehensive immune stimulant. rather Transfer Factor (T.F.) is a

natural killer

> activator like MGN-3, but unlike MGN-3 it teaches natural killer cells

exactly what

> antigens to look for.

> Unlike beta glucan it does not activate macrophages which are the master

controllers of

> the immune system through the cytokine regulated immune cascade.

> Nevertheless transfer factor is a part of Protocol 1.

>

> If one cant understand abstracts from medical journals, try just reading

the last

> sentence, as this usually contains the summary of findings.

>

> moonbeam

>

> 1: Cancer 1996 Nov 1;78(9):1892-1898

>

> Postoperative immunostimulation after complete resection improves survival

of

> patients with stage I nonsmall cell lung carcinoma.

>

> Fujisawa T, Yamaguchi Y.

>

> Department of Surgery, Chiba University School of Medicine, Japan.

>

> BACKGROUND: approximately 40% of primary lung carcinoma patients who die

within

> 1 month after a complete resection have residual tumor in regional or

distant

> organs, emphasizing the importance of postoperative adjuvant therapy. In

this

> study, the effectiveness of transfer factor (TF) and nocardia rubra-cell

wall

> skeleton (N-CWS) as adjuvant therapy for patients with primary, completely

> resected nonsmall cell carcinoma of the lung was evaluated in a randomized

> controlled trial METHODS: A total of 82 patients with Stage I disease who

had a

> complete resection were allocated randomly into 2 groups: TF + N-CWS (n =

41) or

> control (surgery only) (n = 41). RESULTS: The distributions of age, sex,

> histology, differentiation, T classification, tumor size, visceral pleural

> invasion, and the site of origin, were similar in the two groups. The 5-

and

> 10-year disease specific survival rates in the TF + N-CWS group were 85%

and

> 85%, respectively, and those in the control group were 72% and 64%,

> respectively. There was a statistically significant difference between the

two

> groups (P = 0.041). When the survival was analyzed according to clinical

> characteristics, significant differences were observed in patients with no

> visceral pleural invasion or with T1 disease. The frequency of distant

> metastasis was significantly less in the TF + N-CWS group than in the

control

> group. CONCLUSIONS: These results indicate that TF + N-CWS is beneficial

as

> adjuvant therapy after surgical treatment of Stage I nonsmall cell

carcinoma of

> the lung.

>

> Publication Types:

> Clinical trial

> Randomized controlled trial

>

> PMID: 8909308 [PubMed - indexed for MEDLINE]

>

>

>

>

> 2: Zhonghua Zhong Liu Za Zhi 1993 Nov;15(6):435-437

>

> [Effect of hepatocellular carcinoma-specific transfer factor (HCC-S-TF) on

IL-2

> activity and IL-2R expression].

>

> [Article in Chinese]

>

> Pen GY.

>

> Third Military Medical University, Chongqing.

>

> HCC specific transfer factor (S-TF) was extracted from lymphoid tissues of

goats

> immunized with HCC cell suspension. The effect of the S-TF on IL-2

activity and

> IL-2R expression was observed in vitro. The results showed that IL-2

activity

> and IL-2R expression in HCC patients but not in normal subjects could be

> increased by the S-TF. The IL-2 activities and IL-2R expressions in both

normal

> subjects and patients with HCC could not be increased by normal transfer

factor

> (N-TF). This may be one of the anti-tumor mechanisms of S-TF. It suggests

that

> S-TF may be better than N-TF in immunotherapy of human tumors.

>

> PMID: 8200281 [PubMed - indexed for MEDLINE]

>

>

>

>

> 3: Ann Thorac Surg 1992 Mar;53(3):391-396

>

> Adjuvant treatment using transfer factor for bronchogenic carcinoma:

long-term

> follow-up.

>

> Whyte RI, Schork MA, Sloan H, Orringer MB, Kirsh MM.

>

> Section of Thoracic Surgery, University of Michigan, Ann Arbor.

>

> Transfer factor, a dialyzable lymphocyte extract that may act as an immune

> stimulator by transferring antigen-specific immunity between genetically

> dissimilar individuals, was administered in a prospective, randomized

study to

> patients with non-small cell bronchogenic carcinoma. Between 1976 and

1982, 63

> patients who underwent pulmonary resection, mediastinal lymph node

dissection,

> and, when indicated by the presence of mediastinal lymph node involvement,

> mediastinal irradiation were randomized into two groups. Group 1 (n = 28)

> received 1 mL of pooled transfer factor at 3-month intervals after

operation;

> group 2 (n = 35 ) served as controls and received saline solution. There

were no

> statistically significant differences between the two groups with respect

to

> age, sex, tumor histology, stage of disease, or extent of resection. One

patient

> was lost to follow-up at 96 months; follow-up was complete in all others

through

> July 1990. In patients receiving transfer factor, the 2-, 5-, and 10-year

> survival rates were 82%, 64%, and 43% respectively, whereas in controls

they

> were 63%, 43%, and 23%. Survival in patients receiving transfer factor was

> consistently better than in those receiving placebo. Furthermore, survival

in

> patients receiving transfer factor was greater at all stages of disease

for both

> adenocarcinoma and squamous cell carcinoma. Although these long-term

results

> were not statistically significant using survival analysis with covariates

(p =

> 0.08), they confirm our previously reported short-term findings suggesting

that

> administration of transfer factor, either through nonspecific immune

> stimulation, enhancement of cell-mediated immunity, or an as yet undefined

> mechanism, can improve survival in patients with bronchogenic carcinoma.

>

> Publication Types:

> Clinical trial

> Randomized controlled trial

>

> PMID: 1540053 [PubMed - indexed for MEDLINE]

>

>

>

>

> 4: Semin Surg Oncol 1991 Jul;7(4):221-229

>

> Immunotherapy of renal cell cancer.

>

> Crusinberry R, RD.

>

> Department of Urology, University of Iowa, Iowa City 52242.

>

> Immunotherapy of metastatic renal adenocarcinoma (RCC) is currently an

> alternative to cytotoxic chemotherapy. Bacillus Calmette-Guerin has been

> associated with a 22% response rate in small series, but no large-scale

clinical

> trials have been completed. Transfer factor, in combination with other

> immunotherapeutic and chemotherapeutic compounds, has a reported 13%

incidence

> of response. Tumor vaccines have caused clinical response in only 5% of

patients

> while monoclonal antibodies have produced partial remission in one of nine

> patients. Immune RNA has been associated with a 14% overall incidence of

> response. Tumor necrosis factor has not as yet been studied in any

large-scale

> clinical investigations but preliminary studies are not promising.

> Leukocyte-derived and recombinant interferons alone have produced

responses in

> 10-20% of patients with tolerable toxicity. Combinations of interferons or

with

> cytotoxic chemotherapy have produced slightly improved responses with

short

> duration and substantial toxicity. Adoptive immunotherapy using

Interleukin-2

> alone, or with IL-2 plus lymphocyte-activated killer cells, or tumor

> infiltrating lymphocytes or interferons have produced clinical responses

in

> 10-30% of patients treated. Combinations of specific forms of immune

therapy may

> hold promise for better rates of clinical response in the future.

>

> Publication Types:

> Review

> Review, tutorial

>

> PMID: 1925254 [PubMed - indexed for MEDLINE]

>

>

>

>

> 5: Ann Allergy 1989 Mar;62(3):170-176

>

> Biological response modifiers. Interferons, interleukins, and transfer

factor.

>

> Kirkpatrick CH.

>

> Department of Medicine, National Jewish Center for Immunology and

Respiratory

> Medicine, Denver, Colorado.

>

> Natural consequences of knowledge of the mechanisms that regulate immune

> responses are the attempts to modify the immune system in order to

increase

> resistance to infectious diseases and to enhance activity against tumor

cells.

> This review describes the roles of interferons and interleukins in immune

> responses and reviews the experience with transfer factor in treatment of

> certain diseases.

>

> Publication Types:

> Review

> Review, tutorial

>

> PMID: 2466425 [PubMed - indexed for MEDLINE]

>

>

>

>

> 6: Cancer 1988 Apr 15;61(8):1543-1549

>

> A randomized, double-blind, placebo-controlled trial of transfer factor as

> adjuvant therapy for malignant melanoma.

>

> LL, Spitler LE, RE, Minor DR.

>

> M. Aggelar Memorial Laboratory, Children's Hospital of San Francisco,

> California.

>

> One hundred and sixty-eight evaluable patients participated in a

randomized,

> double-blind study of transfer factor (TF) versus placebo as surgical

adjuvant

> therapy of Stage I and Stage II malignant melanoma. Eighty-five patients

> received TF prepared from the leukocytes of healthy volunteer donors;

> eighty-three participants received placebo. Therapy was initiated within

90 days

> of resection of all evident tumor and continued until 2 years of

disease-free

> survival or the occurrence of unresectable dissemination of melanoma.

Known

> prognostic variables were similarly distributed in the treatment and

control

> groups, documenting the randomization efficacy. Three endpoints were

analyzed:

> disease-free interval, time to Stage III metastasis, and survival. After a

> median follow-up period of 24.75 months, there was a trend in favor of the

> placebo group with regard to all three endpoints and this was significant

(P

> less than or equal to 0.05) for time to Stage III metastasis. These

findings

> indicate that TF is not effective as surgical adjuvant therapy of

malignant

> melanoma.

>

> Publication Types:

> Clinical trial

> Randomized controlled trial

>

> PMID: 3280114 [PubMed - indexed for MEDLINE]

>

>

>

>

> 7: J Exp Pathol 1987;3(4):549-564

>

> Clinical trials of transfer factor in malignancy.

>

> Spitler LE, L.

>

> M. Aggelar Memorial Laboratory, Children's Hospital of San Francisco,

> California 94118.

>

> Results of clinical trials of transfer factor therapy in various

malignancies

> have been variable. In non randomized trials, about 300 patients have been

> evaluated, and clinical benefit has been reported in about 1/3 of the

evaluable

> patients. Results of randomized studies are similarly varied. In some

randomized

> trials, clinical benefits of increased disease free survival and prolonged

> survival have been claimed. In other studies, transfer factor has been

reported

> to be of no clinical benefit. In a few studies, results suggest patients

> receiving transfer factor do not do as well as those receiving placebo,

although

> these are only trends, and do not reach the level of statistical

significance.

> There are a number of variables in the design of transfer factor trials,

and

> review of the studies performed to date does not permit a determination of

> which, if any, of these variables is related to the therapeutic outcome. A

> variety of tumor types have been evaluated, and it is not clear which, if

any,

> tumors respond to transfer factor. Similarly, the state of disease and

prior and

> concomitant therapy vary widely in these trials and the impact of these

> variables is unclear. The source and dose of transfer factor also varies.

In

> some studies, attempts have been made to select donors who might have

cellular

> immune reactivity to the tumor being treated, whereas in other studies

normal

> donors have been used. The rationale for the use of normal donors in that

the

> clinical benefit of transfer factor may be related to the non specific

> immunopotentiating effects of this agent rather than the specific transfer

of

> cellular immunity. Finally, the methods of preparation of transfer factor

vary

> and the products used in various studies cannot be compared by standard

biologic

> or biochemical tests currently available. This review of the literature

> regarding the clinical effort of transfer factor in malignancy leads to

the

> conclusion that transfer factor might not be an effective therapy of

cancer. If

> it does have efficacy in certain malignancies, it is unlikely that it will

alone

> have dramatic effects in substantial numbers of patients. Perhaps transfer

> factor may have a role in tumor therapy as an adjuvant to other forms of

therapy

> and as surgery, irradiation, or chemotherapy. In order for the proper

evaluation

> of transfer factor in reproducible comparative studies, it will be

necessary to

> have a standarized reproducible product which can be assessed by

appropriate

> quality control procedures.(ABSTRACT TRUNCATED AT 250 WORDS)

>

> Publication Types:

> Clinical trial

> Review

> Review, tutorial

>

> PMID: 3331650 [PubMed - indexed for MEDLINE]

>

>

>

>

> 8: Nippon Geka Gakkai Zasshi 1985 Sep;86(9):1055-1058

>

> [The results of immunotherapy as an adjunct to the surgical treatment of

primary

> lung cancers].

>

> [Article in Japanese]

>

> Fujisawa T.

>

> A total of 263 primary non-small cell lung cancer patients resected in our

> Institute from March, 1978 to October, 1984 were utilized in order to

evaluate

> the efficacy of transfer factor (TF) immunotherapy as an adjunct to

surgical

> treatment and TF was significantly effective to cases with stage I

diseases, but

> not to stages II, III and IV diseases, indicating that TF could only

suppressed

> micrometastasis existing at the time of surgery. In order to improve the

further

> results of immunotherapy as an adjunct to surgical treatment, we analyzed

> cytotoxic activity against autologous lung cancer and K562 leukemia cells

in

> tumor bearing hosts. Furthermore, we studied the effect of interleukin 2

(IL2)

> activated lymphocyte dialysate on cytotoxic activity against lung cancer

cells.

> When 3 different sources of lymphocytes including peripheral blood

lymphocytes

> (PBL) regional lymphnode cells (LNC) and tumor infiltrating lymphocytes

(TIL)

> were incubated with IL2 for 8 days at 37 degrees C in 5% CO2 atmosphere,

> relatively high cytotoxic activity was demonstrated with 2 major different

> patterns in PBL, LNC and TIL including one systemic predominant and the

other

> local predominant patterns, suggesting that IL2 might be a local or

systemic

> possible immunotherapeutic reagent. Finally, we stimulated lymphocytes

from

> household contact family members with IL2 and MMC treated lung cancer

cells.

> These in vitro modulated T-lymphocytes demonstrated considerable cytotoxic

> activity against the target cells which were used as in vitro

sensitization. The

> dialysate of these in vitro stimulated cells showed specific activity on

> cytotoxicity against lung cancer cells and might be a possible reagent in

stead

> of TF for clinical trial.

>

> PMID: 3878937 [PubMed - indexed for MEDLINE]

>

>

>

>

> 9: Am J Reprod Immunol Microbiol 1985 Jul;8(3):80-83

>

> Effect of transfer factor on tumor-associated immunity and tumor growth of

the

> Dunning R-3327G rat prostate adenocarcinoma.

>

> Shaw MW, Ablin RJ, Guinan PD, Bhatti RA.

>

> Of importance in the design and application of improved or new modalities

of

> treatment are their evaluation on relevant animal models. In the case of

> prostate cancer (PCa) the Dunning R-3327 rat prostate adenocarcinoma

(PCa), and

> its variant sublines, is one such experimental tumor model of its human

> counterpart. In a preliminary study, the effect of transfer factor (TF),

one

> form of passive immunotherapy, on tumor-associated immunity (TAI) and

tumour

> growth and histology of the G subline (a poorly differentiated,

fast-growing,

> androgen sensitive, and poorly metastatic tumour of the Dunning R-3327 rat

PCa)

> has been evaluated. TF prepared from the leukocytes of tumor-bearing

animals and

> nontumor-bearing animals referred to as sensitized (STF) and unsensitized

(UTF),

> respectively, had no significant effect on TAI or tumor size. The only

> noticeable effect of TF in this study was the presence of variable and

moderate

> lymphocytic infiltrates, necrosis, and degenerative-type cells in tumors

of

> animal recipients of STF. The failure to observe significant differences

in TAI

> among tumor bearing and nontumor bearing animals raises doubt in part, of

the

> immunogenicity of the G subline tumor and its appropriateness, at least

for

> subsequent immunological studies. Further factors considered in this

regard, are

> questions of tumor load, including the possible need for the use of

adjuvant,

> and the parameters and sensitivity of immune responsiveness selected for

> evaluation and immunocompetency. Subsequent evaluation of the effect of TF

on

> other more immunogenic variant sublines of the Dunning R-3327 rat tumor

may yet

> provide further and more useful information.

>

> PMID: 4025670 [PubMed - indexed for MEDLINE]

>

>

>

> > and the study results the best

> > product fo= r stimulating the immunesystem beside other products

ofcourse

> > like mentione= d before in this mailgroup.

>

> >

> > I got this from Felix the person who is the main seller of these

> > pro= ducts, so his purpose is to sell a lot of this stuff, but anyhow it

> > is quit= e amazing what the site tells about the experiences with

TRansfer

> > factor pl= us. And the studies I got send home are quite good. Also an

> > independient ra= ndomised study. But maybe you can ask Felix to send

you

> > the same material=

> > he sended me..

> >

> > First, you may want to read the testimonials of successful product

users,

> > a= s they can explain their triumphs with the product far better than I

> > ever c= ould. They're available here:

> > http://www.explode-web-traffic.com/map/testim= onials. This takes a

while

> > to load, but well worth the wait. This page is t= hat extensive and it's

a

> > small representation of the actual testimonial vol= ume. Cancer patients

> > have testified here.

> >

> > Gr. Kees Braam

> > webmaster www.kanker-actueel.nl

>

>

>

> Get HUGE info at http://www.cures for cancer.ws, and post your own links there.

Unsubscribe by sending email to cures for cancer-unsubscribeegroups or by

visiting http://www.bobhurt.com/subunsub.mv

>

>

[Guest guest]

In a message dated 3/9/02 5:57:59 PM Central Standard Time,

careysullins@... writes:

>

> I also do many other supplements and things but I would suggest giving

>

Which on are you suggesting we should take? What company?

Carole

[Guest guest]

Yes, this could easily be a herxeimer reaction. It means you are killing

something.

Thanks,

Doris

----- Original Message -----

From: " stevendupre " <stevendupre@...>

> Hello,

> I have had sore neck glands and a slight fever on my very first day

> taking just one transfer factor capsule. Is this normal?

> Steve Du Pre

[Guest guest]

I assume you are talking about the supplement, " transfer factor. " My dr. has

recommended a different brand which calls its product " Immune support

factors " by chisolm labs (chisolmbio.com). Its supposedly less costly (under

$50 I think). I have had two blood tests since being on it, and due for a

third in a couple of weeks. After the first test, my NKC increased a little,

but my dr. said that the two main products she recommends both provide charts

that show only minimal increases during the first month. However, after the

first month the increases generally are more noticeable. Unfortunately, my

second test showed a DECLINE in NKC, but I was also in the middle of a lupus

flare and both my ANA and cardio crp were elevated. So, I guess the true

test as to whether I will stay on this product, or switch brands, will be

based on my third blood test.

Annette

Annette

[Guest guest]

<<< Has anyone on this list had or know of anyone who has had real

" human " transfer factor taken from a close relative that had contact

with them at onset? >>>

hi cathy - yes - i know a mother who donated to a daughter. this was

years ago - in the '80s. it helped her a while, then, like so many

other things, stopped. the mother was later dx'd with cfs, though

milder than the daughter. it was also prohibitively expensive and time

consuming....

~~~~~~~~~~~~~~~~~~~~~~~~~

" Would they have found nothing, unless nothing was what they wanted to

find? " - Agent Dales, X-Files

@}{~{<<~~~~~~~~~~~~~~~~~~~~

@}{~{<<~~~~~~~~~~~~~~~~~~~~

debbie s. - dlsherman@...

[Guest guest]

www.antibioticfailure.com/je/

transfer factor

> below I will post what I found to be a particularly interesting study

> I found. Not a silver bullet, but perhaps an aid in the arsenal. As

> I have been reading about TF's this evening, I have noticed that

> perhaps not all are created equal, and this study points to specific

> TF vs. non-specific TF.

>

> here is a websight to get you started if your interested:

> http://www.transferfactor.ws/

>

> Just FYI

> Chris

>

>

>

>

> Transfer factor in chronic mucocutaneous candidiasis

>

> Massimo Masi(1), Caterina De Vinci(2), Olavio o Baricordi(3).

>

> (1)Allergology and Clinical Immunology Center, Department of

> Pediatrics, University of Bologna; (2)Experimental Urology Unit,

> Division of Urology - S.Orsola-Malpighi Hospital, Bologna, Italy. (3)

> Department of Genetics, University of Ferrara, Italy

>

> Fifteen patients suffering from chronic mucocutaneous candidiasis

> were treated with an in vitro produced TF specific for Candida

> albicans antigens and/or with TF extracted from pooled buffy coats of

> blood donors. CMI of the patients was assessed using the LMT and the

> LST in presence of candidine. The aim of the study was the clinical

> evaluation of TF treatment and the incidence of positive tests

> before, during, and after therapy. Immunological data were matched

> using the Chi square test. 87 LMT were performed for each antigen

> dose and, at the dilution of 1/50, 58.9% (33/56) tests were positive

> during non-treatment or non-specific TF treatment. On the contrary

> 83.9% (26/31) were positive during specific TF treatment (P<0.05). In

> the LST, a significant decrease of thymidine uptake in the control

> cultures in presence of autologous or AB serum was observed when

> patients were matched according to non-treatment, and both non

> specific (P<0.05) and specific TF treatment (P<0.01). Only during

> specific TF treatment was a significant increase of reactivity

> against the Candida antigen at the highest concentration noticed when

> compared with the period of non specific treatment (P<0.01). Clinical

> observations were encouraging: all but one patient experienced

> significant improvement during treatment with specific TF. These data

> confirm that orally administered specific TF, extracted from induced

> lymphoblastoid cell-lines, increases the incidence of reactivity

> against Candida antigens in the LMT. LST reactivity appeared not

> significantly increased with respect to the periods of non treatment,

> but was significantly increased when it was compared to the non-

> specific TF treatment periods. At the same time, a clinical

> improvement was noticed.

>

>

>

>

[Guest guest]

Thank-you for your post! My son has Chronic Mucocutaneous Candidiasis, which

is a rare form of candidiasis sadly enough. I too have been doing alot of

studying into

TF, glad you shared this site!

Angie

[Guest guest]

In a message dated 9/23/02 7:35:58 PM Pacific Daylight Time,

noo.dle@... writes:

will a stool test or comprehensive stool analysis pick up this rare form of

candida

> (mucocutaneous candidiasis)? thank you

>

[Guest guest]

I honestly do not know the answer to this question.......I would think that

the main question is...would the attending doctor recognize/know what chronic

mucocutaneous candidiasis is and know how to treat it????? I have found this

to be a problem in the past. My son (actually my step-son) had it from the

time he was an infant, inherited it from his birth mother. He had plenty of

signs and symptoms but was not diagnosed until he was two and a half years

old.

[Guest guest]

Here is a transfer factor that is supposedly made specifically for

candida:

ImmunFactor( 1 (Keep refrigerated):

HIV, Pneumocystic carinii, Human tuberculosis, Bovine tuberculosis,

Epstein-Barr Virus (EBV), Herpes 1, Herpes 2, Human herpes virus 6 (

HHV6), Candida albicans, Cryptosporosis, and Mycobacterium avian

Chris

ps. I just ordered a different product from this company for a

different reason, and I'll post in time as to the outcome.

[Guest guest]

do you have a link for this??

Re: transfer factor

>

> Here is a transfer factor that is supposedly made specifically for

> candida:

>

> ImmunFactor( 1 (Keep refrigerated):

>

> HIV, Pneumocystic carinii, Human tuberculosis, Bovine tuberculosis,

> Epstein-Barr Virus (EBV), Herpes 1, Herpes 2, Human herpes virus 6 (

> HHV6), Candida albicans, Cryptosporosis, and Mycobacterium avian

>

>

>

> Chris

> ps. I just ordered a different product from this company for a

> different reason, and I'll post in time as to the outcome.

>

>

>

>

[Guest guest]

Here is the company that makes it:

http://www.chisolmbio.com/

Its not inexpensive though...about $135.- month I think. I spoke to

the owner who was happy to answer my questions. Alot of money, but I

figure if it works....hey.

This site talks about different makes of transfer factor and provides

some studies:

http://www.transferfactor.ws/

Good luck,

Chris

> do you have a link for this??

> Re: transfer factor

>

>

> >

> > Here is a transfer factor that is supposedly made specifically for

> > candida:

> >

> > ImmunFactor( 1 (Keep refrigerated):

> >

> > HIV, Pneumocystic carinii, Human tuberculosis, Bovine

tuberculosis,

> > Epstein-Barr Virus (EBV), Herpes 1, Herpes 2, Human herpes virus

6 (

> > HHV6), Candida albicans, Cryptosporosis, and Mycobacterium avian

> >

> >

> >

> > Chris

> > ps. I just ordered a different product from this company for a

> > different reason, and I'll post in time as to the outcome.

> >

> >

> >

> >